Pipeline
Our unique groundbreaking ProTcell platform has the potential to enable a broad range of future applications including CAR ProTcell and TCR ProTcell for long-lasting, targeted immuno-oncology therapies.
Discover our different projects and ongoing clinical trials in our pipeline.
ProTcell is a T-cell progenitor-based allogeneic cell therapy designed to rebuild a fully polyclonal T-cell compartment in 100 days after an allogenic hematopoietic stem cell transplantation (allo-HSCT), versus the 18 months needed in the current medical practice.
Once infused into the patients, the ProTcells migrate into the patient’s thymus to be differentiated and give rise to a large pool of polyclonal, long-lasting T-cell population able to fight cancers and infections in the long run.
SMART101 is manufactured from peripheral mobilized stem cells (mPB). It is currently studied in 3 phase I/II clinical trials:
- in Europe in patients with severe combined immunodeficiency (SCID) (NCT03879876)
- the ReSET-01 trial in the United States in adult and pediatric patients with high-risk acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL) (NCT04959903).
- the ReSET-02 trial in Europe in adult patients with high-risk AML, ALL or myelodysplastic syndrome (MDS) (NCT05768035)
SMART201 product is the CAR ProTcell product produced from mobilized peripheral blood.